IDEXX Laboratories (IDXX) has been the subject of a variety of financial movements and opinions from analysts and investors alike. Analysts have given the company a consensus rating of \"
Moderate Buy\". Noteworthy, there have been multiple instances of investment firms increasing their holdings in
IDEXX. However, cases of firms reducing their stakes in the company were also reported.
IDEXX's financial performance is also drawing attention, with its shares experiencing a rise of 39.4% within a year and the expectation of better earnings from the company. A major boost was the CEO's transition, making the firm more diagnostics-focused. Their resilience in a tough market environment has been praised, and the company's potential in the growing pet market is being recognized. However, the recent drop in share prices has raised concerns amongst investors, urging them to reconsider their decisions. Given these considerations, Wall Street has set a mean target of $750 for
IDEXX.
Idexx Laboratories IDXX News Analytics from Mon, 04 Aug 2025 07:00:00 GMT to Sat, 21 Mar 2026 01:26:51 GMT -
Rating 7
- Innovation 8
- Information 8
- Rumor 6
